Takeda and Wave Partner to Develop Stereopure Nucleic Acid Therapies for CNS Disorders
By Heather Cartwright
Pharma Deals Review: Vol 2018 Issue 3 (Table of Contents)
Published: 6 Mar-2018
DOI: 10.3833/pdr.v2018.i3.2308 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Demonstrating its commitment to the neuroscience space, Takeda Pharmaceutical has signed a broad, two-component deal with Wave Life Sciences to discover, develop and commercialise rationally designed nucleic acid therapies for genetically defined neurological diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS